GENETICS AND GENOMICS JOURNAL

Biography:

Dr. Eugenie S. Kleinerman serves as Professor in Pediatrics at Anderson Cancer Center, she received her A.B. degree from Washington University in St. Louis, and her MD degree from Duke University. She completed her pediatric residency at the Children’s Hospital National Medical Center in Washington, DC, followed by a fellowship at the National Cancer Institute in Bethesda, MD. She was a Senior Investigator at the NCI-Frederic Cancer Research Facility then recruited to MD Anderson Cancer Center. Dr. Kleinerman was Head of Pediatrics and Children’s Cancer Hospital at MD Anderson from 2001-2015.

She has an international reputation in sarcoma research and the development of novel therapeutic approaches. She identified a new immunotherapy, which led to the Phase I, II & III trials, resulting in the drug’s approval by the EMA in 2009. She is the first to show that EWS-FLI-1 and Notch control vasculogenesis in Ewing’s sarcoma. She received the Distinguished Medical Alumnus Award from Duke University, the Faculty Achievement Award for Clinical Research and Distinguished Alumni Award from Washington University. She is an active member of many scientific advisory committees. She is the author of many papers published in internationally reputed journals. She has received many honors and awards including Fellow American Association for the Advancement of Science (AAAS), 2016 and Women in Health & Medical Science Hearts of Gold Award, 2014.

Research Interests:

Her research interest focuses on new therapies that target the tumor microenvironment to combat osteosarcoma and Ewing’s sarcoma metastases and is pioneering aerosol administration to deliver these therapies into the lungs. She showed that the FAS/FasL pathway plays a critical role in osteosarcoma metastasis to the lung, that the pathway cam be therapeutically targeted and that Fas expression is controlled by the mi-R-17-92 cluster.